Monopar Therapeutics Inc.
Monopar Therapeutics Inc. (MNPR) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · MNPR · as of Jun 8, 2026
Activity summary
Buy transactions
1
P-Purchase only
Sell transactions
7
12 Months
Buy/Sell ratio
0.14
Buy/Sell (by trades)
Overall sentiment
Monopar Therapeutics Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
MNPR insider buying and selling by quarter
MNPR insider selling · MNPR insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · MNPR ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
MNPR executive sell shares · MNPR board member insider trading · MNPR insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Mar 31, 2026 | Robinson Chandler CEO · Director | Option | 6,732 | — | Form 4 |
| Mar 31, 2026 | Robinson Chandler CEO · Director | Other | 1,972 | $108K | Form 4 |
| Mar 31, 2026 | Cittadine Andrew COO | Option | 3,514 | — | Form 4 |
| Mar 31, 2026 | Cittadine Andrew COO | Other | 1,571 | $86K | Form 4 |
| Jan 28, 2025 | Robinson Chandler CEO · Director | Other | 62,815 | — | Form 4 |
| Dec 31, 2025 | Robinson Chandler CEO · Director | Option | 8,724 | — | Form 4 |
| Dec 31, 2025 | Robinson Chandler CEO · Director | Other | 2,558 | $167K | Form 4 |
| Dec 31, 2025 | Cittadine Andrew COO | Option | 4,326 | — | Form 4 |
| Dec 31, 2025 | Cittadine Andrew COO | Other | 1,889 | $123K | Form 4 |
| Dec 26, 2025 | Vu Quan Anh CFO | Purchase | 1,500 | $105K | Form 4 |
| Dec 18, 2025 | KLAUSNER ARTHUR J Director | Sale | 4,660 | $312K | Form 4 |
| Dec 18, 2025 | KLAUSNER ARTHUR J Director | Sale | 461 | $31K | Form 4 |
| Dec 16, 2025 | Hendricks Diane 10 percent owner | Other | 43,499 | — | Form 4 |
| Dec 16, 2025 | KLAUSNER ARTHUR J Director | Other | 7,710 | — | Form 4 |
| Sep 30, 2025 | Cittadine Andrew COO | Option | 4,327 | — | Form 4 |
| Sep 30, 2025 | Cittadine Andrew COO | Other | 1,896 | $155K | Form 4 |
| Sep 30, 2025 | Robinson Chandler CEO · Director | Option | 8,726 | — | Form 4 |
| Sep 30, 2025 | Robinson Chandler CEO · Director | Other | 2,646 | $216K | Form 4 |
| Sep 24, 2025 | Tactic Pharma LLC 10 percent owner | Sale | 550,229 | $35.00M⚡ | Form 4 |
| Jul 14, 2025 | Tsuchimoto Kim R Director | Other | 8,904 | $45 | Form 4 |
| Jul 14, 2025 | Tsuchimoto Kim R Director | Sale | 8,904 | $356K | Form 4 |
| Jul 14, 2025 | STARR CHRISTOPHER M Director | Other | 16,800 | $84 | Form 4 |
| Jul 14, 2025 | STARR CHRISTOPHER M Director | Sale | 16,800 | $672K | Form 4 |
| Jul 14, 2025 | Robinson Chandler CEO · Director | Other | 16,800 | $84 | Form 4 |
| Jul 14, 2025 | Robinson Chandler CEO · Director | Sale | 16,800 | $672K | Form 4 |
Robinson Chandler
CEO · Director
Date
Mar 31
Shares
1,972
Price
$54.79
Value
$108K
Robinson Chandler
CEO · Director
Date
Dec 31
Shares
2,558
Price
$65.30
Value
$167K
Robinson Chandler
CEO · Director
Date
Sep 30
Shares
2,646
Price
$81.67
Value
$216K
Tactic Pharma LLC
10 percent owner
Date
Sep 24
Shares
550,229
Price
$63.61
Value
$35.00M ⚡
Robinson Chandler
CEO · Director
Date
Jul 14
Shares
16,800
Price
$40.00
Value
$672K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About MNPR insider trading
MNPR insider trades
Monopar Therapeutics Inc. (MNPR) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Robinson Chandler (CEO · Director), Cittadine Andrew (COO), KLAUSNER ARTHUR J (Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. MNPR insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Monopar Therapeutics Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
MNPR insider trading · 5 questionsThe insiders of Monopar Therapeutics Inc. (MNPR) include executives and directors such as Robinson Chandler (CEO · Director), Cittadine Andrew (COO), KLAUSNER ARTHUR J (Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026